Clinical Stage Partnering Agreements in Biopharma

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in clinical stage dealmaking

• 2.1. Introduction
• 2.2. Difference between phase I, II and III stage deals
  • 2.2.1. Trends in clinical stage deals
• 2.3. Trends in phase I deals since 2000
  • 2.3.1. Attributes of phase I deals
• 2.4. Trends in phase II deals since 2000
  • 2.4.1. Attributes of phase II deals
• 2.5. Trends in phase III deals since 2000
  • 2.5.1. Attributes of phase III deals
• 2.6. Reasons for entering into clinical stage partnering deals
  • 2.6.1. Licensors reasons for entering clinical stage deals
  • 2.6.2. Licensees reasons for entering clinical stage deals
• 2.7. The future of clinical stage partnering deals

Chapter 3 - Overview of clinical stage deal structure

• 3.1. Introduction
• 3.2. Pure versus multi-component partnering deals
• 3.3. Pure licensing agreement structure
  • 3.3.1. Example pure licensing agreements
  • 3.3.1.a. Case study 1: Coley Pharmaceutical - Dynavax Technologies - June 2007
  • 3.3.1.b. Case study 2: Bristol-Myers Squibb - Pharmacopeia - October 2007
• 3.4. Multicomponent clinical stage partnering agreements
  • 3.4.1. Example multicomponent clinical stage clauses
  • 3.4.1.a. Case study 3: Idera - Merck KGaA - December 2007

Chapter 4 - Leading phase I clinical stage deals

• 4.1. Introduction
• 4.2. Top phase I clinical stage deals by value
• 4.3. Top phase I clinical stage deals signed by bigpharma
• 4.4. Most active phase I clinical stage dealmakers
• 4.5. Bigpharma phase I clinical stage deal activity

Chapter 5 - Leading phase II clinical stage deals

• 5.1. Introduction
• 5.2. Top phase II clinical stage deals by value 70
• 5.3. Top phase II clinical stage deals signed by bigpharma
• 5.4. Most active phase II clinical stage dealmakers
• 5.5. Bigpharma phase II clinical stage deal activity

Chapter 6 - Leading phase III clinical stage deals

• 6.1. Introduction
• 6.2. Top phase III clinical stage deals by value
• 6.3. Top phase III clinical stage deals signed by bigpharma
• 6.4. Most active phase III clinical stage dealmakers
• 6.5. Bigpharma phase III clinical stage deal activity

Chapter 7 - Bigpharma clinical stage partnering agreements

• 7.1. Introduction
• 7.2. How to use clinical stage partnering agreements
• 7.3. Company clinical stage partnering agreement listings
  • Abbott
  • Actavis
  • Akzo Nobel
  • Alcon Labs
  • Allergan
  • Altana
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Bayer Schering Pharma AG
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Chugai
  • CSL
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono KGaA
  • Mitsubishi
  • Novartis AG
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Serono
  • Shionogi Seiyaku
  • Shire
  • Takeda
  • Tanabe Seiyaku
  • TAP Pharmaceuticals
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 8 - Phase I partnering agreement directory 2003-early 2008

• 8.1. Introduction
• 8.2. Company A-Z
• 8.3. By therapy area
  • Accident/Hospital/Trauma
  • Blood/Lymphatic System
  • Cardiovascular
  • Central nervous System
  • Dermatology
  • Gastrointestinal
  • Genetic
  • Genitourinary
  • Autoimmune/Inflammatory
  • Infection
  • Metabolism
  • Musculoskeletal
  • Oncology
  • Respiratory
  • Sensory Organ / Oral Health
  • Delivery
• 8.4. By deal type
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Research
  • Supply

Chapter 9 - Phase II partnering agreement directory 2003-early 2008

• 9.1. Introduction
• 9.2. Company A-Z
• 9.3. By therapy area
  • Accident/Hospital/Trauma
  • Blood/Lymphatic System
  • Cardiovascular
  • Central nervous System
  • Dermatology
  • Gastrointestinal
  • Genetic
  • Genitourinary
  • Autoimmune/Inflammatory
  • Infection
  • Metabolism
  • Musculoskeletal
  • Oncology
  • Respiratory
  • Sensory Organ / Oral Health
  • Delivery
• 9.4. By deal type
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Research
  • Supply

Chapter 10 - Phase III agreement directory 2003-early 2008

• 10.1. Introduction
• 10.2. Company A-Z
• 10.3. By therapy area
  • Accident/Hospital/Trauma
  • Blood/Lymphatic System
  • Cardiovascular
  • Central nervous System
  • Dermatology
  • Gastrointestinal
  • Genetic
  • Genitourinary
  • Autoimmune/Inflammatory
  • Infection
  • Metabolism
  • Musculoskeletal
  • Oncology
  • Respiratory
  • Sensory Organ / Oral Health
  • Delivery
• 10.4. By deal type
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Research
  • Supply

Appendices

• Appendix 1 - Clinical stage partnering references
• Appendix 2 - Resources
• Appendix 3 - Deal type definitions
• Appendix 3 - Deal type definitions
• Appendix 4 - Example clinical stage partnering contract
• About CurrentPartnering
• Recent report titles from CurrentPartnering
• Order Form - Reports
• Order form - Company Dealmaking Profiles

Table of figures

• Figure 1: Definition of clinical phases in dealmaking
• Figure 2: Trends in clinical stage deal announcements, 2000-2007
• Figure 3: Trends in phase I deal announcements, 2000-2007
• Figure 4: Trends in phase II deal announcements, 2000-2007
• Figure 5: Trends in phase III deal announcements, 2000-2007
• Figure 6: Components of the pure licensing deal structure
• Figure 7: Top phase I clinical stage deals by value since 2003
• Figure 8: Bigpharma - top 50 - phase I clinical stage deals since 2003
• Figure 9: Most active phase I clinical stage dealmakers 2003-early 2008
• Figure 10: Bigpharma - top 50 - phase I clinical stage deals since 2003
• Figure 11: Top phase II clinical stage deals by value since 2003
• Figure 12: Bigpharma - top 50 - phase II clinical stage deals since 2003
• Figure 13: Most active phase II clinical stage dealmakers 2003-early 2008
• Figure 14: Bigpharma - top 50 - phase II clinical stage deals since 2003
• Figure 15: Top phase III clinical stage deals by value since 2003
• Figure 16: Bigpharma - top 50 - phase III clinical stage deals since 2003
• Figure 17: Most active phase III clinical stage dealmakers 2003-early 2008
• Figure 18: Bigpharma - top 50 - phase III deals since 2003
• Figure 19: Online partnering resources
• Figure 20: Deal type definitions
• Figure 21: Partnering agreement between Alfacell and Par - Jan 2008